Bowman-Birk inhibitor concentrate reduces colon inflammation in mice with dextran sulfate sodium-induced ulcerative colitis.

Abstract

Bowman-Birk inhibitor concentrate (BBIC) is a soybean extract enriched in the Bowman-Birk inhibitor, a protein protease inhibitor. The Bowman-Birk inhibitor can inhibit proteases released from inflammation mediating cells and suppress superoxide anion radical secretion from immunocytes. This study investigates the ability of Bowman-Birk inhibitor concentrate to inhibit colon inflammation in the dextran sulfate sodium model of ulcerative colitis, an inflammatory bowel disease. When compared to mice on a standard diet, mice given food supplemented with 0.5% BBIC during and after dextran sulfate sodium treatment showed suppression of three of four scored histopathological inflammation criteria (P < 0.01), total histopathological score (P < 0.01), a 15% lower mortality rate (P < 0.01), and a delayed onset of mortality. We conclude that dietary Bowman-Birk inhibitor concentrate can beneficially affect dextran sulfate sodium-treated mice and may be useful in the treatment of human inflammatory bowel diseases, particularly ulcerative colitis.

• Authors: J H Ware, X S Wan, P Newberne, A R Kennedy
• Journal: Digestive diseases and sciences (Dig Dis Sci) Vol. 44 Issue 5 Pg. 986-90 (May 1999) ISSN: 0163-2116 [Print] United States
• PMID: 10235608 (Publication Type: Journal Article, Research Support, U.S. Gov't, P.H.S.)

Chemical References

• Trypsin Inhibitor, Bowman-Birk Soybean
• Trypsin Inhibitors
• Dextran Sulfate

Topics

• Animals
• Colitis, Ulcerative (chemically induced, drug therapy)
• Colon (drug effects)
• Dextran Sulfate
• Disease Models, Animal
• Mice
• Mice, Inbred Strains
• Trypsin Inhibitor, Bowman-Birk Soybean (pharmacology, therapeutic use)
• Trypsin Inhibitors (pharmacology, therapeutic use)